

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF MICHIGAN**

SHANNON O'NEILL, }
Plaintiff, } Case No.
v. }
MILLENDOD THERAPEUTICS, INC., }
CAROLE L. NUECHTERLEIN, }
JAMES M. HINDMAN, GEOFF }
NICHOL, CAROL G. GALLAGHER, }
HABIB J. DABLE, JULIA C. }
OWENS, MARY LYNNE HEDLEY, }
LOUIS J. ARCUDE III, and JOHN }
HOWE, III, }
Defendants. }

Plaintiff Shannon O'Neill (“Plaintiff”), upon information and belief, including an examination and inquiry conducted by and through her counsel, except as to those allegations pertaining to Plaintiff, which are alleged upon personal belief, alleges the following for her Complaint:

NATURE AND SUMMARY OF THE ACTION

1. Plaintiff brings this action against Millendo Therapeutics, Inc. (“Millendo” or the “Company”) and the members of its Board of Directors (the “Board” or the “Individual Defendants”) for their violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), 15 U.S.C. §§ 78n(a), 78t(a), and U.S. Securities and Exchange Commission (“SEC”) Rule 14a-9,

17 C.F.R. § 240.14a-9, arising out of their attempt to merge the Company with Tempest Therapeutics, Inc. (“Tempest”) through Millendo’s subsidiary Mars Merger Corp. (the “Proposed Transaction”).

2. On March 29, 2021, Millendo announced that it had entered into an Agreement and Plan of Merger pursuant to which, Millendo stockholders will own approximately 18.5% of the outstanding shares of the combined company upon closing of the deal and former Tempest stockholders will own approximately 81.5% of the outstanding shares of the combined company.

3. On May 11, 2021, Millendo filed a Form 424B3 (the “Prospectus”) with the SEC. The Prospectus is materially deficient and misleading because, *inter alia*, it fails to disclose material information regarding: (i) the Company’s and Tempest’s financial projections and the financial analyses performed by the Board’s financial advisor, SVB Leerink LLC (“SVB Leerink”); and (ii) potential conflicts of interest faced by SVB Leerink. Defendants authorized the issuance of the false and misleading Prospectus in violation of Sections 14(a) and 20(a) of the Exchange Act.

4. Without additional information, the Prospectus is materially misleading in violation of the federal securities laws.

JURISDICTION AND VENUE

5. This Court has jurisdiction over the claims asserted herein for violations of Sections 14(a) and 20(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder pursuant to Section 27 of the Exchange Act, 15 U.S.C. § 78aa, and 28 U.S.C. § 1331 (federal question jurisdiction).

6. This Court has jurisdiction over the defendants because each defendant is either a corporation that conducts business in and maintains operations within this District or is an individual with sufficient minimum contacts with this District so as to make the exercise of jurisdiction by this Court permissible under traditional notions of fair play and substantial justice.

7. Venue is proper in this District pursuant to 28 U.S.C. § 1391 because Plaintiff's claims arose in this District, where a substantial portion of the actionable conduct took place, where most of the documents are electronically stored, and where the evidence exists. Millendo is headquartered in this District. Moreover, each of the Individual Defendants, as Company officers or directors, has extensive contacts within this District.

THE PARTIES

8. Plaintiff is, and has been at all times relevant hereto, a continuous stockholder of Millendo.

9. Defendant Millendo is a Delaware corporation with its principal executive offices located at 110 Miller Avenue, Suite 100, Ann Arbor, Michigan 48104. Millendo's common stock trades on the NASDAQ Global Select Market under the ticker symbol "MLND."

10. Defendant Carole L. Nuechterlein has served as a director of the Company since March 2017.

11. Defendant James M. Hindman has served as a director of the Company since June 2016.

12. Defendant Geoff Nichol has served as a director of the Company since December 2019.

13. Defendant Carol G. Gallagher has served as a director of the Company since September 2012.

14. Defendant Habib J. Dable has served as a director of the Company since September 2018.

15. Defendant Julia C. Owens has served as Executive Chair of the Board since February 1, 2021, and a director of the Company since its inception in 2012.

16. Defendant Mary Lynne Hedley has served as a director of the Company since March 2017.

17. Defendant Louis J. Arcudi III has served as Chief Executive Officer, President, Principal Executive Officer, and a director of the Company since February 1, 2021.

18. Defendant John Howe, III has served as a director of the Company since June 2015.

19. Defendants identified in paragraphs 10-18 are referred to herein as the “Board” or the “Individual Defendants.”

20. Relevant non-party Tempest is a clinical-stage oncology company focused on leveraging its scientific understanding of cancer biology and medicinal chemistry to develop and advance novel orally available therapies for the treatment of solid tumors. Tempest’s principal executive offices are located at 7000 Shoreline Court, Suite 275, South San Francisco, California 94080.

SUBSTANTIVE ALLEGATIONS

Background of the Company and the Proposed Transaction

21. Millendo is a biopharmaceutical company that was previously primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. In April 2020, the Board decided to discontinue the development of livoletide, an unacylated ghrelin analogue, as a potential treatment for Prader-Willi syndrome (“PWS”) based upon results from its Phase 2b trial. In addition, in June 2020, the Board decided to cease investing in

the development of nevanimibe as a potential treatment for classic congenital adrenal hyperplasia, (“CAH”) based on an interim review of data from its Phase 2b trial. Finally, in January 2021, the Board also decided to discontinue the investment in MLE-301, a neurokinin 3 receptor (“NK3R”) antagonist Millendo was developing for the treatment of menopausal vasomotor symptoms (“VMS”), based on an analysis of the pharmacokinetic and pharmacodynamic data from the ongoing single ascending dose portion of the Phase 1 study conducted in healthy male volunteers. Given Millendo’s limited expected financing options, it began exploring an expanded range of strategic alternatives that included, but was not limited to, the potential sale or merger of Millendo or its assets.

22. On March 29, 2021, Millendo and Tempest issued a joint press release announcing the Proposed Transaction which states, in relevant part:

SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.---- Tempest Therapeutics, Inc. (“Tempest”), a privately-held clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (Nasdaq: MLND) (“Millendo”), announced today that they have entered into a definitive agreement under which Millendo will merge with Tempest in an all-stock transaction. The combined company will focus on advancing Tempest’s oncology pipeline of small molecule therapeutics that have the potential to address a wide range of tumors. Upon shareholder approval, the combined company is expected to operate under the name Tempest Therapeutics and trade on the Nasdaq Capital Market under the ticker symbol TPST.

In support of the merger, Tempest has secured commitments from a premier syndicate of healthcare investors comprised of Versant

Ventures, Rock Springs Capital, F-Prime Capital, Monashee Investment Management, Quan Capital, Lyfe Capital, Maven Investment Partners US, Lilly Asia Ventures and Eight Roads Ventures for a \$30 million PIPE financing that is expected to close concurrent with the completion of the merger. Together with the cash expected from both companies at closing, the net proceeds of the merger and financing are expected to fund the further development of Tempest's three oncology programs and operate the company into early 2023. The financing and merger are expected to close in the first half of 2021.

"We are very pleased to announce this proposed merger with Millendo Therapeutics, which will facilitate the advancement of our broad pipeline of targeted oncology programs, including TPST-1495 and TPST-1120, which are both progressing in the clinic with encouraging early signs of clinical benefit," said Tom Dubensky, Ph.D., chief executive officer of Tempest. "Together with our recently announced clinical collaboration with Roche to investigate TPST-1120 in a randomized frontline hepatocellular carcinoma study, this has been a highly productive quarter for Tempest that sets the stage for additional potential catalysts from our proprietary oncology programs. The transition of Tempest to a public company enhances our ability to fund these potentially important product candidates, as well as consider additional programs with exciting new targets."

Tempest's oncology pipeline is led by two clinical programs, TPST-1495 and TPST-1120, with broad potential across multiple tumor types. TPST-1495 is an antagonist selective for two receptors in the prostaglandin (PGE2) pathway, EP2 and EP4, which promote both tumor growth and the proliferation of suppressive immune cell populations. Tempest is currently evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of TPST-1495 in a multicenter Phase 1a/1b dose and schedule optimization study in patients with advanced solid tumors, with a focus on known prostaglandin-driven tumors such as colorectal cancer, lung adenocarcinoma and urothelial cancer. Tempest expects to report topline data from this study prior to the end of 2021, as well as data from planned monotherapy dose expansion and combination studies in 2022. TPST-1120 is designed to be a selective antagonist of proliferator-activated receptor alpha (PPAR α) which is a

transcription factor that regulates the expression of target genes that promote angiogenesis and enable a cellular metabolic pathway known as fatty acid oxidation. TPST-1120 has completed monotherapy dose escalation and is progressing through a combination dose escalation study with nivolumab. This summer, Tempest expects F. Hoffmann-La Roche Ltd to initiate a global, randomized Phase 1b/2 clinical study in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic HCC not previously treated with systemic therapy, pursuant to a recently announced collaboration between the companies. Tempest expects to report topline data from this study by year-end 2022.

“Millendo Therapeutics’ strategic review was a thorough and thoughtful process. We believe we have found a partner that offers not only the greatest value for our existing shareholders but also promising targeted oncology product candidates for patients living with cancer,” said Louis Arcudi, chief executive officer of Millendo.

About the Proposed Merger

Millendo stockholders are expected to own approximately 18.5% of the combined company and pre-merger Tempest stockholders will own approximately 81.5% of the combined company. The percentage of the combined company that Millendo’s stockholders will own as of the close of the transaction is subject to adjustment based on the amount of Millendo’s net cash at the closing date.

Upon closing of the transaction, Millendo will be renamed Tempest Therapeutics, Inc. and will be headquartered in South San Francisco, CA. Stephen Brady and Tom Dubensky, Ph.D., will serve as chief executive officer and president, respectively, of the combined company. The merger agreement provides that the Board of Directors of the combined company will be comprised of seven members. The merger agreement has been approved by the Board of Directors of each company, and the transaction is expected to close in the first half of 2021, subject to approvals by the stockholders of each company, the effectiveness of a Prospectus filed with the U.S. Securities and Exchange Commission to register the shares of Millendo common

stock to be issued in connection with the merger, the completion of a PIPE financing, and other customary closing conditions.

SVB Leerink is serving as the exclusive financial advisor to Millendo and WilmerHale is serving as legal counsel. Piper Sandler is serving as the exclusive financial advisor to Tempest and Sidley Austin is serving as legal counsel.

The Prospectus Misleads Millendo Stockholders by Omitting Material Information

23. On May 11, 2021, Millendo filed the materially misleading and incomplete Prospectus with the SEC. Designed to convince Millendo's stockholders to vote in favor of the Proposed Transaction, the Prospectus is rendered misleading by the omission of critical information concerning: (i) the Company's and Tempest's financial projections and the financial analyses performed by the Board's financial advisor, SVB Leerink; and (ii) potential conflicts of interest faced by SVB Leerink.

Material Omissions Concerning the Company's and Tempest's Financial Projections and SVB Leerink's Financial Analyses

24. The Prospectus omits material information regarding the Company's and Tempest's financial projections.

25. The Prospectus sets forth that in connection with rendering its fairness opinion, SVB Leerink reviewed "certain internal information, primarily related to expense forecasts, furnished to SVB Leerink by the managements of Millendo and Tempest, respectively, and approved for SVB Leerink's use by Millendo[.]"

Prospectus at 120. The Prospectus fails, however, to disclose any financial projections for Millendo or Tempest, including the expense forecasts provided to SVB Leerink by Millendo and Tempest management.

26. The Prospectus also fails to disclose SVB Leerink's basis for attributing an equity value of \$158,400,000 to Tempest, inclusive of \$30,000,000 in committed concurrent financing by new and existing investors. *Id.* at 121.

27. Additionally, the Prospectus fails to disclose any liquidation analysis for Millendo or quantification of the projected cash available to Millendo stockholders in a liquidation.

28. The Prospectus also omits material information regarding SVB Leerink's financial analyses.

29. The Prospectus describes SVB Leerink's fairness opinion and the various valuation analyses performed in support of its opinion. However, the description of SVB Leerink's fairness opinion and analyses fails to include key inputs and assumptions underlying these analyses. Without this information, as described below, Millendo's public stockholders are unable to fully understand these analyses and, thus, are unable to determine what weight, if any, to place on SVB Leerink's fairness opinion in determining whether to vote in favor of the Proposed Transaction.

30. With respect to SVB Leerink's *Tempest Therapeutics Valuation Analysis – Selected Biopharma Initial Public Offering Step-Ups, Tempest Therapeutics Valuation Analysis – Selected Biopharma Initial Public Offerings, and Tempest Therapeutics Valuation Analysis – Selected Biopharma Public Companies*, the Prospectus fails to disclose SVB Leerink's basis for selecting the companies observed, including with respect to the individual companies' financial and operating characteristics.

31. With respect to SVB Leerink's *Tempest Therapeutics Valuation Analysis – Selected Biopharma Public Companies*, the Prospectus fails to disclose: (i) the fully-diluted outstanding shares utilized; and (ii) SVB Leerink's basis for applying a 25% liquidity discount.

32. Without such undisclosed information, Millendo stockholders cannot evaluate for themselves whether the financial analyses performed by SVB Leerink were based on reliable inputs and assumptions or whether they were prepared with an eye toward ensuring that a positive fairness opinion could be rendered in connection with the Proposed Transaction. In other words, full disclosure of the omissions identified above is required in order to ensure that stockholders can fully evaluate the extent to which SVB Leerink's opinion and analyses should factor into their decision whether to vote in favor of or against the Proposed Transaction.

33. The omission of this material information renders certain portions of the Prospectus materially misleading, including, *inter alia*, the following sections of the Prospectus: “Opinion of Millendo’s Financial Advisor” and “Millendo Reasons for the Merger.”

Material Omissions Concerning SVB Leerink’s Potential Conflicts of Interest

34. The Prospectus fails to disclose material information concerning the potential conflicts of interest faced by SVB Leerink.

35. The Prospectus states:

SVB Leerink LLC is a full-service securities firm engaged in securities trading and brokerage activities as well as investment banking and financial advisory services. SVB Leerink has provided certain investment banking services to Millendo from time to time, for which it has received compensation. In the ordinary course of business, SVB Leerink and its affiliates may, in the future, provide commercial and investment banking services to Millendo, Tempest or their respective affiliates and would expect to receive customary fees for the rendering of such services.

Id. at 125. Yet, the Prospectus fails to disclose the details of the investment banking services SVB Leerink provided to Millendo, and the related compensation received.

36. Additionally, the Prospectus fails to disclose the details of any services SVB Leerink provided to Tempest or its affiliates in the previous two years, including the timing and nature of any services provided, as well as the

related compensation SVB Leerink received or expects to receive for any services provided.

37. Full disclosure of investment banker compensation and all potential conflicts is required due to the central role played by investment banks in the evaluation, exploration, selection, and implementation of strategic alternatives.

38. The omission of this material information renders certain portions of the Prospectus materially misleading, including, *inter alia*, the following section of the Prospectus “Opinion of Millendo’s Financial Advisor.”

39. Accordingly, Plaintiff seeks injunctive and other equitable relief to prevent the irreparable injury that Company stockholders will continue to suffer absent judicial intervention.

CLAIMS FOR RELIEF

COUNT I

Claims Against All Defendants for Violations of Section 14(a) of the Exchange Act and Rule 14a-9 Promulgated Thereunder

40. Plaintiff repeats all previous allegations as if set forth in full.

41. During the relevant period, defendants disseminated the false and misleading Prospectus specified above, which failed to disclose material facts necessary to make the statements, in light of the circumstances under which they were made, not misleading in violation of Section 14(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder.

42. By virtue of their positions within the Company, the defendants were aware of this information and of their duty to disclose this information in the Prospectus. The Prospectus was prepared, reviewed, and/or disseminated by the defendants. It misrepresented and/or omitted material facts, including material information about the Company's and Tempest's financial projections, the financial analyses performed by SVB Leerink, and potential conflicts of interest faced by SVB Leerink. The defendants were at least negligent in filing the Prospectus with these materially false and misleading statements.

43. The omissions and false and misleading statements in the Prospectus are material in that a reasonable stockholder would consider them important in deciding how to vote on the Proposed Transaction.

44. By reason of the foregoing, the defendants have violated Section 14(a) of the Exchange Act and SEC Rule 14a-9(a) promulgated thereunder.

45. Because of the false and misleading statements in the Prospectus, Plaintiff is threatened with irreparable harm, rendering money damages inadequate. Therefore, injunctive relief is appropriate to ensure defendants' misconduct is corrected.

COUNT II

Claims Against the Individual Defendants for Violations of Section 20(a) of the Exchange Act

46. Plaintiff repeats all previous allegations as if set forth in full.

47. The Individual Defendants acted as controlling persons of Millendo within the meaning of Section 20(a) of the Exchange Act as alleged herein. By virtue of their positions as officers and/or directors of Millendo, and participation in and/or awareness of the Company's operations and/or intimate knowledge of the false statements contained in the Prospectus filed with the SEC, they had the power to influence and control and did influence and control, directly or indirectly, the decision-making of the Company, including the content and dissemination of the various statements which Plaintiff contends are false and misleading.

48. Each of the Individual Defendants was provided with or had unlimited access to copies of the Prospectus and other statements alleged by Plaintiff to be misleading prior to and/or shortly after these statements were issued and had the ability to prevent the issuance of the statements or cause the statements to be corrected.

49. In particular, each of the Individual Defendants had direct and supervisory involvement in the day-to-day operations of the Company, and, therefore, is presumed to have had the power to control or influence the particular transactions giving rise to the securities violations as alleged herein, and exercised the same. The Prospectus at issue contains the unanimous recommendation of each of the Individual Defendants to approve the Proposed Transaction. They were, thus, directly involved in the making of the Prospectus.

50. In addition, as the Prospectus sets forth at length, and as described herein, the Individual Defendants were each involved in negotiating, reviewing, and approving the Proposed Transaction. The Prospectus purports to describe the various issues and information that they reviewed and considered—descriptions the Company directors had input into.

51. By virtue of the foregoing, the Individual Defendants have violated Section 20(a) of the Exchange Act.

52. As set forth above, the Individual Defendants had the ability to exercise control over and did control a person or persons who have each violated Section 14(a) and SEC Rule 14a-9, promulgated thereunder, by their acts and omissions as alleged herein. By virtue of their positions as controlling persons, these defendants are liable pursuant to Section 20(a) of the Exchange Act. As a direct and proximate result of defendants' conduct, Millendo's stockholders will be irreparably harmed.

PRAYER FOR RELIEF

WHEREFORE, Plaintiff demands judgment and preliminary and permanent relief, including injunctive relief, in her favor on behalf of Millendo, and against defendants, as follows:

A. Preliminarily and permanently enjoining defendants and all persons acting in concert with them from proceeding with, consummating, or

- closing the Proposed Transaction and any vote on the Proposed Transaction;
- B. In the event defendants consummate the Proposed Transaction, rescinding it and setting it aside or awarding rescissory damages to Plaintiff;
- C. Directing the Individual Defendants to disseminate a Prospectus that does not contain any untrue statements of material fact and that states all material facts required in it or necessary to make the statements contained therein not misleading;
- D. Declaring that defendants violated Sections 14(a) and/or 20(a) of the Exchange Act, as well as SEC Rule 14a-9 promulgated thereunder;
- E. Awarding Plaintiff the costs of this action, including reasonable allowance for Plaintiff's attorneys' and experts' fees; and
- F. Granting such other and further relief as this Court may deem just and proper.

JURY DEMAND

Plaintiff demands a trial by jury.

Dated: June 9, 2021

WEISSLAW LLP

By /s/ Richard A. Acocelli

Richard A. Acocelli

1500 Broadway, 16th Floor

New York, New York 10036

Tel: (212) 682-3025

Fax: (212) 682-3010

Email: racocelli@weisslawllp.com

Attorneys for Plaintiff

OF COUNSEL

BRAGAR EAGEL & SQUIRE, P.C.

Alexandra B. Raymond

810 Seventh Avenue, Suite 620

New York, NY 10019

Tel: (646) 860-9158

Fax: (212) 214-0506

Email: raymond@bespc.com

Attorneys for Plaintiff